Glenmark Pharmaceuticals launches 3-in-1 inhaler therapy for COPD in India

Glenmark Pharmaceuticals announced the launch of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD).

This new triple therapy innovation comes with multiple benefits: it offers significant bronchodilation (making breathing easier), reduces risk of severe attacks, and eliminates dependence on multiple inhalers. The reduction in risk of severe attacks decreases the requirement for hospitalization, a benefit of high significance in current prevailing situation.

AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the country. COPD is a very common, serious and debilitating lung disease which like hypertension or diabetes, requires personalized treatment over the rest of the patient's life.

 

Powered by Capital Market - Live News